

# PRODUCT INFORMATION




## KB2115

Item No. 10011054

**CAS Registry No.:** 355129-15-6  
**Formal Name:** 3-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino-3-oxo-propanoic acid

**Synonym:** Eprotirome  
**MF:** C<sub>18</sub>H<sub>17</sub>Br<sub>2</sub>NO<sub>5</sub>  
**FW:** 487.1  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 202, 217, 249 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

KB2115 is supplied as a crystalline solid. A stock solution may be made by dissolving the KB2115 in the solvent of choice, which should be purged with an inert gas. KB2115 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of KB2115 in these solvents is approximately 30 mg/ml.

KB2115 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, KB2115 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. KB2115 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

The thyroid hormones, thyroxine (T4) and triiodothyronine (T3), promote the reduction of plasma cholesterol levels and induce weight loss. However when administered in high doses, thyroid hormones produce undesirable side effects in the heart, bone and muscle. KB2115 is a synthetic thyroid hormone mimetic. At a dose of 50-200 µg administered to humans once-daily for 14 days, KB2115 lowers total and low-density lipoprotein cholesterol up to 40% without affecting high-density lipoprotein cholesterol levels and without deleterious side effects to the cardiovascular system.<sup>1</sup> Unlike the statin class of drugs which decrease cholesterol synthesis, KB2115 stimulates cholesterol catabolism to bile acids without affecting cholesterol synthesis.<sup>1</sup>

### Reference

1. Berkenstam, A., Kristensen, J., Mellström, K., *et al.* The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. *Proc. Nat. Acad. Sci. USA* **105**(2), 663-667 (2008).

**WARNING**  
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

**SAFETY DATA**  
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

**WARRANTY AND LIMITATION OF REMEDY**  
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/20/2022

### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM